文献速递类风湿关节炎

真实世界比较研究:Janus激酶抑制剂在类风湿关节炎患者中的疗效——ANSWER队列研究

Real-world comparative study of the efficacy of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

该多中心回顾性研究从ANSWER队列数据库选取622例接受托法替布、巴瑞替尼、培非替尼或乌帕替尼治疗的类风湿关节炎患者,采用倾向评分逆概率治疗加权匹配四组基线特征,比较启动后6个月的CDAI、CRP、mHAQ及缓解率,发现四种JAK抑制剂疗效与安全性无显著差异。

要点

  • 四种JAK抑制剂治疗6个月 retention 和停药率无显著差异。
  • 6个月时CDAI均值、CDAI缓解率和CDAI-LDA率在四组间无显著差异。
  • 基线CDAI、基线CRP、基线糖皮质激素剂量和既往生物/靶向合成DMARDs数量是CDAI-LDA达成的预测因素。

核心结论

  • 托法替布、巴瑞替尼、培非替尼和乌帕替尼治疗类风湿关节炎的疗效和安全性无显著差异。

研究设计与样本

  • 多中心回顾性研究,从ANSWER队列数据库选取622例接受托法替布、巴瑞替尼、培非替尼或乌帕替尼治疗的患者。
  • 采用倾向评分逆概率治疗加权(IPTW)在四组间匹配患者背景。

主要发现

  • 四种JAK抑制剂治疗组至6个月的 retention 率和停药率无显著差异。
  • 启动后6个月CDAI均值、CDAI缓解率及CDAI-LDA率在四组间无显著差异。
  • 基线CDAI是CDAI-LDA达成的预测因素(托法替布:OR 1.09,P < 0.001;巴瑞替尼:OR 1.07,P < 0.001)。
  • 基线CRP是托法替布组CDAI-LDA达成的预测因素(OR 1.32,P = 0.049)。
  • 基线糖皮质激素剂量(巴瑞替尼:OR 1.18,95% CI 1.01-1.38,P = 0.035)和既往生物/靶向合成DMARDs数量(巴瑞替尼:OR 1.36,P = 0.004)是巴瑞替尼组CDAI-LDA达成的预测因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This multicentre, retrospective study compared the efficacy and safety of tofacitinib, baricitinib, peficitinib and upadacitinib in real-world clinical settings after minimizing selection bias and adjusting the confounding patient characteristics. METHOD: The 622 patients were selected from the ANSWER cohort database and treated with tofacitinib (TOF), baricitinib (BAR), peficitinib (PEF) or upadacitinib (UPA). The patient's background was matched using propensity score-based inverse probability of treatment weighting (IPTW) among four treatment groups. The values of Clinical Disease Activity Index (CDAI), C-reactive protein (CRP), and modified Health Assessment Questionnaire (mHAQ) after drug initiation and the remission or low disease activity (LDA) rates of CDAI at 6 months after drug initiation were compared among the four groups. Further, the predictive factor for TOF and BAR efficacy was analysed. RESULTS: The retention and discontinuation rates until 6 months after drug initiations were not significantly different among the four JAK inhibitors treatment groups. Mean CDAI value, CDAI remission rate, and CDAI-LDA rate at 6 months after drug initiation were not significantly different among treatment groups. Baseline CDAI (TOFA: OR 1.09, P < 0.001; BARI: OR 1.07, P < 0.001), baseline CRP (TOFA: OR 1.32, P = 0.049), baseline glucocorticoid dose (BARI: OR 1.18, 95% CI 1.01-1.38, P = 0.035), a number of previous biological or targeted synthetic disease-modifying antirheumatic drugs (biological/targeted synthetic DMARDs) (BARI: OR 1.36, P = 0.004) were predictive factors for resistance to CDAI-LDA achievement to JAK inhibitor treatment. CONCLUSION: The efficacy and safety of TOF, BAR, PEF and UPA were not significantly different for the treatment of patients with rheumatoid arthritis.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Hayashi S, Tachibana S, Maeda T, et al. Real-world comparative study of the efficacy of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study. Rheumatology (Oxford). 2024. PMID: 37924201. doi:10.1093/rheumatology/kead543

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。